The Winter 2020 edition of the newsletter on SWOG's Lung-MAP precision medicine trial is out. Lung-MAP is NCI's first precision trial, and tests new treatments for non-small cell cancer in partnership with the National Cancer Institute, Foundation for the National Institutes of Health, and Friends of Cancer Research.

The newsletter gives a grateful accounting of progress made during this remarkable year, with over 900 study registrations. It also also includes links to the latest Lung-MAP manuscript, published in The Lancet Oncology, and a list of new study leaders. Read the newsletter here.

Other Recent Stories

SWOG Front Line Banner
Jul 9, 2021
There are many ways we can improve the lives of patients with cancer. Ensuring their safety is on that list.